ReviewExperimental hematology & oncology2026
Ubiquitin-centered post-translational modification crosstalk orchestrates tumor immunity and immunotherapy response.
Review in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Radiomics: Current Applications and Future Directions.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Remarkable progress has been made in cancer immunotherapy in recent years; however, it still faces challenges such as limited response rates, resistance, and immune-related adverse events. Ubiquitination, a key post-translational modification (PTM) of proteins, is indispensable for regulating various tumor immunity-related processes. Through the dynamic balance between ubiquitin ligases and deubiquitinases, this PTM fine-tunes the strength and duration of immune responses, influencing tumor recognition and immune evasion. Accumulating evidence reveals that ubiquitination does not act alone but cooperates and competes with other PTMs-such as phosphorylation, acetylation, SUMOylation, neddylation, and glycosylation-to form a multilayered regulatory network that determines the immune landscape and therapeutic responsiveness. This review systematically summarizes the molecular mechanisms by which ubiquitination-related enzymes modulate the tumor immune microenvironment and immune evasion. Moreover, we highlight emerging insights into the crosstalk between ubiquitination and other PTMs, which collectively govern the stability and signaling of immune regulators. Finally, we discuss the translational potential of targeting the ubiquitin system, emphasizing opportunities and challenges in developing selective ubiquitin modulators and designing rational combination immunotherapies. Decoding this integrated PTM network will not only deepen mechanistic understanding of tumor immunity but also open new avenues for precision immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.